CYP19A1 and breast cancer: In the subgroup of patients with triple-positive BC, aromatase inhibitors (co-administered with LHRH analogs when clinically indicated) were employed in 50.8% of cases, while tamoxifen was used in 14.1% of patients; the remaining patients received both tamoxifen and aromatase inhibitors as endocrine treatment, with a switch strategy.